Overview

* GeneDx Q3 2025 rev grows 52% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company raises full-year revenue guidance to $425-$428 mln

Outlook

* GeneDx ( WGS ) raises full-year 2025 revenue guidance to $425-$428 mln

* Company expects 53%-55% growth in exome and genome revenue for 2025

* GeneDx ( WGS ) anticipates 70%-71% adjusted gross margin for full year 2025

Result Drivers

* EXOME AND GENOME GROWTH - Exome and genome test revenue grew 65% yr/yr, driven by a 33% increase in test volumes

* FDA DESIGNATION - FDA Breakthrough Device Designation for ExomeDx™ and GenomeDx™ highlights innovative leadership

* NEWBORN SCREENING LEADERSHIP - Co leads in genomic newborn screening as sole commercial provider for new programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $116.70 $104.10

Revenue mln mln (7

Analysts

)

Q3 Beat $0.49 $0.39 (5

Adjusted Analysts

EPS )

Q3 $14.70

Adjusted mln

Net

Income

Q3 Net -$7.60

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for GeneDx Holdings Corp ( WGS ) is $125.00, about 4.5% below its October 27 closing price of $130.66

* The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 60 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)